3-(2,2,2-trimethylhydrazine)propionate has been researched along with atenolol in 1 studies
| Studies (3-(2,2,2-trimethylhydrazine)propionate) | Trials (3-(2,2,2-trimethylhydrazine)propionate) | Recent Studies (post-2010) (3-(2,2,2-trimethylhydrazine)propionate) | Studies (atenolol) | Trials (atenolol) | Recent Studies (post-2010) (atenolol) |
|---|---|---|---|---|---|
| 251 | 35 | 105 | 5,473 | 1,950 | 852 |
| Protein | Taxonomy | 3-(2,2,2-trimethylhydrazine)propionate (IC50) | atenolol (IC50) |
|---|---|---|---|
| Beta-1 adrenergic receptor | Homo sapiens (human) | 0.7468 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.23 | |
| Alpha-1A adrenergic receptor | Homo sapiens (human) | 0.23 | |
| Alpha-1B adrenergic receptor | Homo sapiens (human) | 0.23 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mamchur, SE; Sankevitch, TV; Stepatcheva, TA; Teplyakov, AT | 1 |
1 trial(s) available for 3-(2,2,2-trimethylhydrazine)propionate and atenolol
| Article | Year |
|---|---|
[The use of fatty acid beta-oxidation inhibitor mildronate as monotherapy or in combination with atenolol in patients with left ventricular dysfunction after myocardial infarction].
Topics: Adrenergic beta-Antagonists; Atenolol; Cardiovascular Agents; Drug Therapy, Combination; Humans; Male; Methylhydrazines; Middle Aged; Mitochondrial Trifunctional Protein; Multienzyme Complexes; Myocardial Infarction; Ventricular Dysfunction, Left | 2003 |